Illumina Oncology - Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)

26 September 2023

Eric Duncavage, MD, explains how patients with AML can benefit from whole-genome sequencing testing at diagnosis and after treatment for minimal or measurable residual disease (MRD) assessment. Dr. Duncavage is the director of the sections of Hematopathology and Molecular Oncology and professor of Pathology and Immunology at Washington University in St. Louis. Read more about WGS in AML diagnosis and monitoring here: https:/.htmlmkt.illumina.com/2016012194 #bloodcancerawareness Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illumina
Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.